Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

RespireRx Pharmaceuticals Inc RSPI

RespireRx Pharmaceuticals Inc. develops treatments to combat disorders caused by disruption of neuronal signaling. The Company is developing treatment options that address conditions, such as obstructive sleep apnea (OSA), attention deficit hyperactivity disorder, epilepsy, acute and chronic pain, including inflammatory and neuropathic pain, and recovery from spinal cord injury (SCI), which are conditions that affect millions of people, as well as certain orphan disorders such as GRIA. It also considers developing treatment options for other conditions based on results of preclinical and clinical studies to date. The Company has two business units. ResolutionRx unit holds its pharmaceutical cannabinoids platform, and is developing compounds that target the body’s endocannabinoid system, and in particular, the re-purposing of dronabinol for the treatment of OSA. EndeavourRx is its neuromodulators platform, which is made up of two programs: AMPAkines program and GABAkines program.


PINL:RSPI - Post by User

Post by whytestockson Jan 22, 2024 4:00pm
44 Views
Post# 35839611

RespireRx Pharmaceuticals Inc. Announces the Appointment of

RespireRx Pharmaceuticals Inc. Announces the Appointment of
JUST IN: $RSPI RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of DirectorsGlen Rock, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neur...RSPI - RespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors

<< Previous
Bullboard Posts